Page 100 - Haematologica August 2018

S. Moody et al. References
1. Du MQ. MALT lymphoma: A paradigm of NF-kappaB dysregulation. Semin Cancer Biol. 2016;39:49-60.
2. van Maldegem F, Wormhoudt TA, Mulder MM, et al. Chlamydia psittaci-negative ocu- lar adnexal marginal zone B-cell lymphomas have biased VH4-34 immunoglobulin gene expression and proliferate in a distinct inflammatory environment. Leukemia. 2012;26(7):1647-1653.
3. Mannami T, Yoshino T, Oshima K, et al. Clinical, histopathological, and immuno- genetic analysis of ocular adnexal lympho- proliferative disorders: characterization of malt lymphoma and reactive lymphoid hyperplasia. Mod Pathol. 2001;14(7):641- 649.
4. Bahler DW, Szankasi P, Kulkarni S, et al. Use of similar immunoglobulin VH gene seg- ments by MALT lymphomas of the ocular adnexa. Mod Pathol. 2009;22(6):833-838.
5. Zhu D, Bhatt S, Lu X, et al. Chlamydophila psittaci-negative ocular adnexal marginal zone lymphomas express self polyreactive B-cell receptors. Leukemia. 2015;29(7):1587- 1599.
6. Dagklis A, Ponzoni M, Govi S, et al. Immunoglobulin gene repertoire in ocular adnexal lymphomas: hints on the nature of the antigenic stimulation. Leukemia. 2012;26(4):814-821.
7. Bende RJ, Aarts WM, Riedl RG, et al. Among B cell non-Hodgkin's lymphomas, MALT lymphomas express a unique anti- body repertoire with frequent rheumatoid factor reactivity. J Exp Med. 2005;201 (8):1229-1241.
8. Bahler DW, Miklos JA, Swerdlow SH. Ongoing Ig gene hypermutation in salivary gland mucosa- associated lymphoid tissue- type lymphomas. Blood. 1997;89(9):3335- 3344.
9. Miklos JA, Swerdlow SH, Bahler DW. Salivary gland mucosa-associated lymphoid tissue lymphoma immunoglobulin V(H) genes show frequent use of V1-69 with dis- tinctive CDR3 features. Blood. 2000;95(12): 3878-3884.
10. Hamoudi RA, Appert A, Ye H, et al. Differential expression of NF-kappaB target genes in MALT lymphoma with and with- out chromosome translocation: insights into molecular mechanism. Leukemia. 2010;24(8):1487-1497.
11. Ye H, Liu H, Attygalle A, et al. Variable fre- quencies of t(11;18)(q21;q21) in MALT lym- phomas of different sites: significant associ- ation with CagA strains of H pylori in gas- tric MALT lymphoma. Blood. 2003;102(3): 1012-1018.
12. Ye H, Gong L, Liu H, et al. MALT lym- phoma with t(14;18)(q32;q21)/IGH-MALT1 is characterized by strong cytoplasmic MALT1 and BCL10 expression. J Pathol. 2005;205(3):293-301.
13. Streubel B, Simonitsch-Klupp I, Mullauer L, et al. Variable frequencies of MALT lym- phoma-associated genetic aberrations in MALT lymphomas of different sites.
ciency. Clin Exp Immunol. 2016;183(2):221- 14. Chanudet E, Ye H, Ferry J, et al. A20 deletion 229.
Leukemia. 2004;18(10):1722-1726.
is associated with copy number gain at the TNFA/B/C locus and occurs preferentially in translocation-negative MALT lymphoma of the ocular adnexa and salivary glands. J Pathol. 2009;217(3):420-430.
15. Honma K, Tsuzuki S, Nakagawa M, et al. TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non- Hodgkin lymphomas. Blood. 2009;114(12):2467-2475.
16. Bi Y, Zeng N, Chanudet E, et al. A20 inacti- vation in ocular adnexal MALT lymphoma. Haematologica. 2012;97(6):926-930.
17. Moody S, Escudero-Ibarz L, Wang M, et al. Significant association between TNFAIP3 inactivation and biased immunoglobulin heavy chain variable region 4-34 usage in mucosa-associated lymphoid tissue lym- phoma. J Pathol. 2017;243(1):3-8.
18. Clipson A, Wang M, de Leval L, et al. KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct geno- type. Leukemia. 2015;29(5):1177-1185.
19. Wang M, Escudero-Ibarz L, Moody S, et al. Somatic Mutation Screening Using Archival Formalin-Fixed, Paraffin-Embedded Tissues by Fluidigm Multiplex PCR and Illumina Sequencing. J Mol Diagn. 2015;17(5):521- 532.
20. Ansell SM, Akasaka T, McPhail E, et al. t(X;14)(p11;q32) in MALT lymphoma involving GPR34 reveals a role for GPR34 in tumor cell growth. Blood. 2012;120(19):3949-3957.
21. Johansson P, Klein-Hitpass L, Grabellus F, et al. Recurrent mutations in NF-kappaB path- way components, KMT2D, and NOTCH1/2 in ocular adnexal MALT-type marginal zone lymphomas. Oncotarget. 2016;7(38):62627-62639.
22. Baens M, Finalet FJ, Tousseyn T, et al. t(X;14)(p11.4;q32.33) is recurrent in margin- al zone lymphoma and up-regulates GPR34. Haematologica. 2012;97(2):184-188.
23. Akasaka T, Lee YF, Novak AJ, et al. Clinical, histopathological, and molecular features of mucosa-associated lymphoid tissue (MALT) lymphoma carrying the t(X;14) (p11;q32)/GPR34-immunoglobulin heavy chain gene. Leuk Lymphoma. 2017;58(9):1- 4.
24. Perissi V, Aggarwal A, Glass CK, Rose DW, Rosenfeld MG. A corepressor/coactivator exchange complex required for transcrip- tional activation by nuclear receptors and other regulated transcription factors. Cell. 2004;116(4):511-526.
25. Schmidt J, Gong S, Marafioti T, et al. Genome-wide analysis of pediatric-type fol- licular lymphoma reveals low genetic com- plexity and recurrent alterations of TNFRSF14 gene. Blood. 2016;128(8):1101- 1111.
26. Shibata D, Weiss LM. Epstein-Barr virus- associated gastric adenocarcinoma. Am J Pathol. 1992;140:769-774.
27. Elgizouli M, Lowe DM, Speckmann C, et al. Activating PI3Kdelta mutations in a cohort of 669 patients with primary immunodefi-
28. Zhang J, Grubor V, Love CL, et al. Genetic heterogeneity of diffuse large B-cell lym- phoma. Proc Natl Acad Sci USA. 2013;110(4):1398-1403.
29. Crank MC, Grossman JK, Moir S, et al. Mutations in PIK3CD can cause hyper IgM syndrome (HIGM) associated with increased cancer susceptibility. J Clin Immunol. 2014;34(3):272-276.
30. Rajagopal S, Shenoy SK. GPCR desensitiza- tion: Acute and prolonged phases. Cell Signal. 2018;41:9-16.
31. Zhou XE, He Y, de Waal PW, et al. Identification of Phosphorylation Codes for Arrestin Recruitment by G Protein-Coupled Receptors. Cell. 2017;170(3):457-469.
32. Hasegawa H, Patel N, Ettehadieh E, Li P, Lim AC. Topogenesis and cell surface trafficking of GPR34 are facilitated by positive-inside rule that effects through a tri-basic motif in the first intracellular loop. Biochim Biophys Acta. 2016;1863(7 Pt A):1534-1551.
33. Fanelli F, De Benedetti PG, Raimondi F, Seeber M. Computational modeling of intramolecular and intermolecular commu- nication in GPCRs. Curr Protein Pept Sci. 2009;10(2):173-185.
34. Lagane B, Chow KY, Balabanian K, et al. CXCR4 dimerization and beta-arrestin- mediated signaling account for the enhanced chemotaxis to CXCL12 in WHIM syndrome. Blood. 2008;112(1):34-44.
35. Cao Y, Hunter ZR, Liu X, et al. The WHIM- like CXCR4(S338X) somatic mutation acti- vates AKT and ERK, and promotes resist- ance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia. Leukemia. 2015;29(1): 169-176.
36. Nakagawa M, Schmitz R, Xiao W, et al. Gain-of-function CCR4 mutations in adult T cell leukemia/lymphoma. J Exp Med. 2014;211(13):2497-2505.
37. Ikubo M, Inoue A, Nakamura S, et al. Structure-activity relationships of lysophos- phatidylserine analogs as agonists of G-pro- tein-coupled receptors GPR34, P2Y10, and GPR174. J Med Chem. 2015;58(10):4204- 4219.
38. Aoki J, Nagai Y, Hosono H, Inoue K, Arai H. Structure and function of phosphatidylser- ine-specific phospholipase A1. Biochim Biophys Acta. 2002;1582(1-3):26-32.
39. Lee AY, Phan TK, Hulett MD, Korner H. The relationship between CCR6 and its binding partners: does the CCR6-CCL20 axis have to be extended? Cytokine. 2015;72(1):97-101.
40. Zuo B, Li M, Liu Y, et al. G-protein coupled receptor 34 activates Erk and phosphatidyli- nositol 3-kinase/Akt pathways and func- tions as alternative pathway to mediate p185Bcr-Abl-induced transformation and leukemogenesis. Leuk Lymphoma. 2015;56(7):2170-2181.
41. Jung H, Yoo HY, Lee SH, et al. The muta- tional landscape of ocular marginal zone lymphoma identifies frequent alterations in TNFAIP3 followed by mutations in TBL1XR1 and CREBBP. Oncotarget. 2017;8(10):17038-17049.
1336
haematologica | 2018; 103(8)